Advertisements


Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer

Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer.....»»

Category: topSource: seekingalphaJun 12th, 2019

Denali Therapeutics started at buy with $35 stock price target at Instinet

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchSep 13th, 2019

Denali Therapeutics initiated with a Buy at Nomura Instinet

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

Denali Therapeutics doses first patient in Phase 1b study of DNL151

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 4th, 2019

$4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time

The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering per.....»»

Category: topSource: bizjournalsSep 3rd, 2019

Therapeutics startup raises $65M in latest round to fight kidney disease

Chinook Therapeutics is based in Vancouver, B.C., but its CEO lives and works in Seattle — and he's looking to for space in the city to support six to 12 additional employees......»»

Category: topSource: bizjournalsAug 23rd, 2019

Rare disease biotech SpringWorks Therapeutics files for a $115 million IPO

SpringWorks Ther.....»»

Category: futuresSource: nasdaqAug 16th, 2019

Denali Therapeutics initiated with a Buy at BTIG

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 9th, 2019

Denali Therapeutics reports Q2 EPS (61c), consensus (46c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 6th, 2019

Denali Therapeutics announces Sanofi dosing of DNL758 in Phase 1 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 5th, 2019

Chiasma Intends To Redeem Itself With Multiple Catalysts In The Coming Months

Chiasma Intends To Redeem Itself With Multiple Catalysts In The Coming Months.....»»

Category: topSource: seekingalphaAug 1st, 2019

Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

Roche has extended, yet again, its tender offer to Spark Therapeutics in connection with the proposed $4.3 billion purchase of the Philadelphia gene therapy pioneer. For those keeping track, this is the fifth time the companies announced a new deadl.....»»

Category: topSource: bizjournalsJul 31st, 2019

Kalytera Therapeutics: Banking On A Partnership For This Diluted CBD Medical Play With Upcoming Catalysts

Kalytera Therapeutics: Banking On A Partnership For This Diluted CBD Medical Play With Upcoming Catalysts.....»»

Category: topSource: seekingalphaJul 22nd, 2019

LogicBio Therapeutics receives rare pediatric disease designation for LB-001

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 16th, 2019

Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease......»»

Category: worldSource: nytJul 11th, 2019

UNC breakthrough could accelerate gene editing therapeutics

A breakthrough technique coming out of Chapel Hill has the potential to accelerate gene editing therapies, bringing more drugs to patients – and markets – quicker......»»

Category: topSource: bizjournalsJul 10th, 2019

Why Amicus Therapeutics" Stock Perked Up in June

What happened Shares of rare disease specialist Amicus Therapeutics NASDAQ FOLD gained a healthy 10 7 in June according to data from S amp P Global Market Intelligence What sparked this upswing Amicus stock appears to have been the beneficiary of a rising.....»»

Category: futuresSource: nasdaqJul 5th, 2019

First Week of August 16th Options Trading For Denali Therapeutics (DNLI)

Stock Options Channel.....»»

Category: topSource: redinewsJul 1st, 2019

Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine o.....»»

Category: topSource: insidermonkeyJun 29th, 2019

Denali Therapeutics initiated with a Buy at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 26th, 2019

Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals

Aldeyra Therapeutics Inc. shares were down 29% in premarket trade Tuesday, after the company said a trial of a treatment for.....»»

Category: topSource: marketwatchJun 25th, 2019